Tokyo Tape
Sign in
← Otsuka Holdings

Quarterly report · Q1

4578.TEDINET S100TCFM
Period2024-01-01 → 2024-03-31
Filed2024-04-30
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 47
MetricValuePeriodScopeSource row
Revenue¥519.5bn2024-01-01 → 2024-03-31Cons.Revenue IFRS
Revenue¥2.02T2023-01-01 → 2023-12-31Cons.Revenue IFRS (5-year summary)
Revenue¥448.3bn2023-01-01 → 2023-03-31Cons.Revenue IFRS
Operating income¥92.0bn2024-01-01 → 2024-03-31Cons.Operating profit loss IFRS
Operating income¥76.8bn2023-01-01 → 2023-03-31Cons.Operating profit loss IFRS
Profit before tax¥100.1bn2024-01-01 → 2024-03-31Cons.Profit loss before tax IFRS
Profit before tax¥142.7bn2023-01-01 → 2023-12-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥79.2bn2023-01-01 → 2023-03-31Cons.Profit loss before tax IFRS
Net income (owners)¥77.4bn2024-01-01 → 2024-03-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥121.6bn2023-01-01 → 2023-12-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥61.4bn2023-01-01 → 2023-03-31Cons.Profit loss attributable to owners of parent IFRS
Net income¥78.9bn2024-01-01 → 2024-03-31Cons.Profit loss IFRS
Net income¥62.7bn2023-01-01 → 2023-03-31Cons.Profit loss IFRS
Total assets¥3.45Tat 2024-03-31Cons.Assets IFRS
Total assets¥3.36Tat 2023-12-31Cons.Assets IFRS
Total assets¥3.13Tat 2023-03-31Cons.Total assets IFRS (5-year summary)
Total liabilities¥894.5bnat 2024-03-31Cons.Liabilities IFRS
Total liabilities¥924.9bnat 2023-12-31Cons.Liabilities IFRS
Net assets / equity¥2.56Tat 2024-03-31Cons.Equity IFRS
Net assets / equity¥2.44Tat 2023-12-31Cons.Equity IFRS
Net assets / equity¥2.32Tat 2023-03-31Cons.Equity IFRS
Net assets / equity¥2.26Tat 2022-12-31dCons.Equity IFRS
Equity (owners)¥2.51Tat 2024-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥2.39Tat 2023-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥2.28Tat 2023-03-31Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥411.6bnat 2024-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥513.3bnat 2023-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥477.1bnat 2023-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥471.6bnat 2022-12-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥36.4bn2024-01-01 → 2024-03-31Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥283.2bn2023-01-01 → 2023-12-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥71.9bn2023-01-01 → 2023-03-31Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥91.5bn2024-01-01 → 2024-03-31Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥190.5bn2023-01-01 → 2023-12-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥35.8bn2023-01-01 → 2023-03-31Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥58.7bn2024-01-01 → 2024-03-31Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥60.3bn2023-01-01 → 2023-12-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥32.7bn2023-01-01 → 2023-03-31Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥142.592024-01-01 → 2024-03-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥224.12023-01-01 → 2023-12-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥113.22023-01-01 → 2023-03-31Cons.Basic earnings loss per share IFRS
EPS (diluted)¥142.592024-01-01 → 2024-03-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥224.12023-01-01 → 2023-12-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥113.182023-01-01 → 2023-03-31Cons.Diluted earnings loss per share IFRS
Equity ratio72.8%at 2024-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio71.2%at 2023-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio72.8%at 2023-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 44
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2024-01-01 → 2024-03-31¥27.3bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2024-01-01 → 2024-03-31¥26.4bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2024-01-01 → 2024-03-31¥872m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2024-01-01 → 2024-03-31¥1.9bn
Reconciling Itemsreconcilingrevenue2024-01-01 → 2024-03-31−¥881m
Reconciling Itemsreconcilingrevenue intersegment2024-01-01 → 2024-03-31−¥881m
Reconciling Itemsreconcilingsegment profit2024-01-01 → 2024-03-31−¥10.8bn
jpcrp040300-q1r_E21183-000Consumer Productsreportable segmentrevenue2024-01-01 → 2024-03-31¥7.3bn
jpcrp040300-q1r_E21183-000Consumer Productsreportable segmentrevenue external2024-01-01 → 2024-03-31¥7.3bn
jpcrp040300-q1r_E21183-000Consumer Productsreportable segmentrevenue intersegment2024-01-01 → 2024-03-31¥1m
jpcrp040300-q1r_E21183-000Consumer Productsreportable segmentsegment profit2024-01-01 → 2024-03-31¥4.3bn
jpcrp040300-q1r_E21183-000Nutraceuticalsreportable segmentrevenue2024-01-01 → 2024-03-31¥126.2bn
jpcrp040300-q1r_E21183-000Nutraceuticalsreportable segmentrevenue external2024-01-01 → 2024-03-31¥126.2bn
jpcrp040300-q1r_E21183-000Nutraceuticalsreportable segmentrevenue intersegment2024-01-01 → 2024-03-31¥6m
jpcrp040300-q1r_E21183-000Nutraceuticalsreportable segmentsegment profit2024-01-01 → 2024-03-31¥16.8bn
jpcrp040300-q1r_E21183-000Pharmaceuticalsreportable segmentrevenue2024-01-01 → 2024-03-31¥359.6bn
jpcrp040300-q1r_E21183-000Pharmaceuticalsreportable segmentrevenue external2024-01-01 → 2024-03-31¥359.6bn
jpcrp040300-q1r_E21183-000Pharmaceuticalsreportable segmentsegment profit2024-01-01 → 2024-03-31¥79.8bn
—segment totalrevenue2024-01-01 → 2024-03-31¥520.4bn
—segment totalrevenue external2024-01-01 → 2024-03-31¥519.5bn
—segment totalrevenue intersegment2024-01-01 → 2024-03-31¥881m
—segment totalsegment profit2024-01-01 → 2024-03-31¥102.8bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2023-01-01 → 2023-03-31¥27.3bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2023-01-01 → 2023-03-31¥26.6bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2023-01-01 → 2023-03-31¥723m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2023-01-01 → 2023-03-31¥3.1bn
Reconciling Itemsreconcilingrevenue2023-01-01 → 2023-03-31−¥742m
Reconciling Itemsreconcilingrevenue intersegment2023-01-01 → 2023-03-31−¥742m
Reconciling Itemsreconcilingsegment profit2023-01-01 → 2023-03-31−¥12.9bn
jpcrp040300-q1r_E21183-000Consumer Productsreportable segmentrevenue2023-01-01 → 2023-03-31¥8.2bn
jpcrp040300-q1r_E21183-000Consumer Productsreportable segmentrevenue external2023-01-01 → 2023-03-31¥8.2bn
jpcrp040300-q1r_E21183-000Consumer Productsreportable segmentrevenue intersegment2023-01-01 → 2023-03-31¥4m
jpcrp040300-q1r_E21183-000Consumer Productsreportable segmentsegment profit2023-01-01 → 2023-03-31¥2.2bn
jpcrp040300-q1r_E21183-000Nutraceuticalsreportable segmentrevenue2023-01-01 → 2023-03-31¥104.0bn
jpcrp040300-q1r_E21183-000Nutraceuticalsreportable segmentrevenue external2023-01-01 → 2023-03-31¥104.0bn
jpcrp040300-q1r_E21183-000Nutraceuticalsreportable segmentrevenue intersegment2023-01-01 → 2023-03-31¥13m
jpcrp040300-q1r_E21183-000Nutraceuticalsreportable segmentsegment profit2023-01-01 → 2023-03-31¥10.8bn
jpcrp040300-q1r_E21183-000Pharmaceuticalsreportable segmentrevenue2023-01-01 → 2023-03-31¥309.5bn
jpcrp040300-q1r_E21183-000Pharmaceuticalsreportable segmentrevenue external2023-01-01 → 2023-03-31¥309.5bn
jpcrp040300-q1r_E21183-000Pharmaceuticalsreportable segmentsegment profit2023-01-01 → 2023-03-31¥73.6bn
—segment totalrevenue2023-01-01 → 2023-03-31¥449.1bn
—segment totalrevenue external2023-01-01 → 2023-03-31¥448.3bn
—segment totalrevenue intersegment2023-01-01 → 2023-03-31¥742m
—segment totalsegment profit2023-01-01 → 2023-03-31¥89.7bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 694
ItemContextValueUnit
Purchase of treasury shares ss IFRSPrior1YTDDuration_RetainedEarningsIFRSMember－JPY
Purchase of treasury shares ss IFRSPrior1YTDDuration_RemeasurementsOfDefinedBenefitPlansIFRSMember－JPY
Purchase of treasury shares ss IFRSPrior1YTDDuration_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember－JPY
Dividends ss IFRSPrior1YTDDuration_ShareCapitalIFRSMember－JPY
Dividends ss IFRSPrior1YTDDuration_CapitalSurplusIFRSMember－JPY
Dividends ss IFRSPrior1YTDDuration_TreasurySharesIFRSMember－JPY
Dividends ss IFRSPrior1YTDDuration_RetainedEarningsIFRSMember-27131000000JPY
Dividends ss IFRSPrior1YTDDuration_RemeasurementsOfDefinedBenefitPlansIFRSMember－JPY
Dividends ss IFRSPrior1YTDDuration_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember－JPY
Share based payment transactions ss IFRSPrior1YTDDuration_ShareCapitalIFRSMember－JPY
Share based payment transactions ss IFRSPrior1YTDDuration_CapitalSurplusIFRSMember144000000JPY
Share based payment transactions ss IFRSPrior1YTDDuration_TreasurySharesIFRSMember－JPY
Share based payment transactions ss IFRSPrior1YTDDuration_RetainedEarningsIFRSMember－JPY
Share based payment transactions ss IFRSPrior1YTDDuration_RemeasurementsOfDefinedBenefitPlansIFRSMember－JPY
Share based payment transactions ss IFRSPrior1YTDDuration_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember－JPY
Changes in ownership interest in subsidiaries ss IFRSPrior1YTDDuration_ShareCapitalIFRSMember－JPY
Changes in ownership interest in subsidiaries ss IFRSPrior1YTDDuration_CapitalSurplusIFRSMember－JPY
Changes in ownership interest in subsidiaries ss IFRSPrior1YTDDuration_TreasurySharesIFRSMember－JPY
Changes in ownership interest in subsidiaries ss IFRSPrior1YTDDuration_RetainedEarningsIFRSMember－JPY
Changes in ownership interest in subsidiaries ss IFRSPrior1YTDDuration_RemeasurementsOfDefinedBenefitPlansIFRSMember－JPY
Changes in ownership interest in subsidiaries ss IFRSPrior1YTDDuration_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember－JPY
Transfer from other components of equity to retained earnings ss IFRSPrior1YTDDuration_ShareCapitalIFRSMember－JPY
Transfer from other components of equity to retained earnings ss IFRSPrior1YTDDuration_CapitalSurplusIFRSMember－JPY
Transfer from other components of equity to retained earnings ss IFRSPrior1YTDDuration_TreasurySharesIFRSMember－JPY
Transfer from other components of equity to retained earnings ss IFRSPrior1YTDDuration_RetainedEarningsIFRSMember7000000JPY
Transfer from other components of equity to retained earnings ss IFRSPrior1YTDDuration_RemeasurementsOfDefinedBenefitPlansIFRSMember-34000000JPY
Transfer from other components of equity to retained earnings ss IFRSPrior1YTDDuration_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember27000000JPY
Total transactions with owners IFRSPrior1YTDDuration_ShareCapitalIFRSMember－JPY
Total transactions with owners IFRSPrior1YTDDuration_CapitalSurplusIFRSMember144000000JPY
Total transactions with owners IFRSPrior1YTDDuration_TreasurySharesIFRSMember-0JPY
Total transactions with owners IFRSPrior1YTDDuration_RetainedEarningsIFRSMember-27124000000JPY
Total transactions with owners IFRSPrior1YTDDuration_RemeasurementsOfDefinedBenefitPlansIFRSMember-34000000JPY
Total transactions with owners IFRSPrior1YTDDuration_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember27000000JPY
Equity IFRSPrior1QuarterInstant_ShareCapitalIFRSMember81690000000JPY
Equity IFRSPrior1QuarterInstant_CapitalSurplusIFRSMember506724000000JPY
Equity IFRSPrior1QuarterInstant_TreasurySharesIFRSMember-44858000000JPY
Equity IFRSPrior1QuarterInstant_RetainedEarningsIFRSMember1587375000000JPY
Equity IFRSPrior1QuarterInstant_RemeasurementsOfDefinedBenefitPlansIFRSMember－JPY
Equity IFRSPrior1QuarterInstant_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember45485000000JPY
Equity IFRSPrior2YearInstant_ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember87503000000JPY
Equity IFRSPrior2YearInstant_EffectivePortionOfCashFlowHedgesIFRSMember20000000JPY
Equity IFRSPrior2YearInstant_OtherComponentsOfEquityIFRSMember128773000000JPY
Equity IFRSPrior2YearInstant_EquityAttributableToOwnersOfParentIFRSMember2225255000000JPY
Equity IFRSPrior2YearInstant_NonControllingInterestsIFRSMember37114000000JPY
Equity IFRSPrior2YearInstant2262369000000JPY
Profit loss IFRSPrior1YTDDuration_ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember－JPY
Profit loss IFRSPrior1YTDDuration_EffectivePortionOfCashFlowHedgesIFRSMember－JPY
Profit loss IFRSPrior1YTDDuration_OtherComponentsOfEquityIFRSMember－JPY
Profit loss IFRSPrior1YTDDuration_EquityAttributableToOwnersOfParentIFRSMember61430000000JPY
Profit loss IFRSPrior1YTDDuration_NonControllingInterestsIFRSMember1232000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2023-12-31pass rounding
balance sheet identityconsolidated 2024-03-31pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2023-01-01/2023-03-31pass
statement vs summary · net income attributable to parentconsolidated 2024-01-01/2024-03-31pass
statement vs summary · operating cash flowconsolidated 2023-01-01/2023-03-31pass
statement vs summary · operating cash flowconsolidated 2024-01-01/2024-03-31pass
statement vs summary · revenueconsolidated 2023-01-01/2023-03-31pass
statement vs summary · revenueconsolidated 2024-01-01/2024-03-31pass
statement vs summary · total assetsconsolidated 2023-12-31pass
statement vs summary · total assetsconsolidated 2024-03-31pass